These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 7730906)

  • 1. Data monitoring in clinical trials: the case for stochastic curtailment.
    Davis BR; Hardy RJ
    J Clin Epidemiol; 1994 Sep; 47(9):1033-42. PubMed ID: 7730906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stochastic curtailment tests for phase II trial with time-to-event outcome using the concept of relative time in the case of non-proportional hazards.
    Sharma P; Phadnis MA
    J Biopharm Stat; 2024 Jul; 34(4):596-611. PubMed ID: 37574976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stopping clinical trials because of treatment ineffectiveness: a comparison of a futility design with a method of stochastic curtailment.
    Whitehead J; Matsushita T
    Stat Med; 2003 Mar; 22(5):677-87. PubMed ID: 12587099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of futility in clinical trials.
    Snapinn S; Chen MG; Jiang Q; Koutsoukos T
    Pharm Stat; 2006; 5(4):273-81. PubMed ID: 17128426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple imputation for early stopping of a complex clinical trial.
    Betensky RA
    Biometrics; 1998 Mar; 54(1):229-42. PubMed ID: 9544518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Futility interim monitoring with control of type I and II error probabilities using the interim Z-value or confidence limit.
    Lachin JM
    Clin Trials; 2009 Dec; 6(6):565-73. PubMed ID: 19933716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A general formulation for a one-sided group sequential design.
    Moser BK; George SL
    Clin Trials; 2005; 2(6):519-28. PubMed ID: 16422312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Curtailment in single-arm two-stage phase II oncology trials.
    Kunz CU; Kieser M
    Biom J; 2012 Jul; 54(4):445-56. PubMed ID: 22610516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adaptive Designs with Discrete Test Statistics and Consideration of Overrunning.
    Schmidt R; Burkhardt B; Faldum A
    Methods Inf Med; 2015; 54(5):434-46. PubMed ID: 26429500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conditional power as an aid in making interim decisions in observational studies.
    Walker AM
    Eur J Epidemiol; 2018 Sep; 33(9):777-784. PubMed ID: 29808341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interim futility analysis with intermediate endpoints.
    Goldman B; LeBlanc M; Crowley J
    Clin Trials; 2008; 5(1):14-22. PubMed ID: 18283075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bayesian predictive approach to interim monitoring in clinical trials.
    Dmitrienko A; Wang MD
    Stat Med; 2006 Jul; 25(13):2178-95. PubMed ID: 16007570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early termination of clinical trials with prolonged observation of individual patients: a case study.
    van Es GA; Tijssen JG; Lubsen J; van Strik R
    Stat Med; 1987 Dec; 6(8):927-37. PubMed ID: 3438618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multi-arm group sequential designs with a simultaneous stopping rule.
    Urach S; Posch M
    Stat Med; 2016 Dec; 35(30):5536-5550. PubMed ID: 27550822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Practical aspects in data monitoring: a brief review.
    Demets DL
    Stat Med; 1987; 6(7):753-60. PubMed ID: 3321314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Some design considerations incorporating early futility for single-arm clinical trials with time-to-event primary endpoints using Weibull distribution.
    Waleed M; He J; Phadnis MA
    Pharm Stat; 2021 May; 20(3):610-644. PubMed ID: 33565236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.
    Lewis RJ; Lipsky AM; Berry DA
    Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stochastically curtailed phase II clinical trials.
    Ayanlowo AO; Redden DT
    Stat Med; 2007 Mar; 26(7):1462-72. PubMed ID: 16900560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CP function: an alpha spending function based on conditional power.
    Jiang Z; Wang L; Li C; Xia J; Wang W
    Stat Med; 2014 Nov; 33(26):4501-14. PubMed ID: 25100033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of methods for futility stopping based on conditional power.
    Lachin JM
    Stat Med; 2005 Sep; 24(18):2747-64. PubMed ID: 16134130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.